Oslo, Norway, April 29, 2025 - The Ordinary General Meeting of Lytix Biopharma AS ("Lytix" or the "Company") was held on April 29, 2025. All proposed resolutions on the agenda were approved.

As part of the General Meeting, a new Board of Directors was elected in line with the recommendation from the Nomination and Compensation Committee to further reinforce the company. The newly appointed board members bring broad and complementary experience across business development, oncology, fundraising, clinical development, regulatory strategy, and financial oversight. These additions will strengthen the Lytix team and enhance Lytix's chances of quickly bringing new therapeutic options to patients with cancer and create value for the shareholders.

The new board consists of the following members:

• Eric Falcand (Chair): More than 37 years of international leadership and management experience in the pharmaceutical industry; he has led over 50 licensing and partnership agreements globally, including transformative M&A, many of which focused on oncology and immuno-oncology innovations.

• Julie Dehaene-Puype: Pharmaceutical executive with 25 years of international experience in General Management, Commercial Operations, Sales & Marketing, New Products Development and Regulatory Affairs.

• Claus Andersson: More than 25+ years of venture experience and experience from more than 20 international boards

• Marie-Louise Fjällskog: More than 25 years of experience in clinical oncology, translational research, and drug development.

• Brynjar Forbergskog: CEO of Saturn Invest AS and responsible for evolving Torghatten ASA into one of the largest transportation groups in the Nordic region

• Kjetil Hestdal: Senior Life Science Executive and previously the Chief Executive Officer of Photocure ASA - a commercial-stage company focused on bladder cancer

Eric Falcand, Julie Dehaene-Puype and Claus Andersson will complement the continuing members of the board and collectively provide a strong foundation for the company's future direction.

"I am very honored to join Lytix as Chair of the Board and to work alongside such a diverse and experienced team," said Eric Falcand, newly elected Chair. "Lytix has a promising technology platform and a clear ambition to advance their immuno-oncology drug candidates to the benefit of patients. Together with the board and the management, I look forward to contributing to the company's strategic growth and long-term value creation."

"We are very pleased to welcome our new chairman and the new board members," said Øystein Rekdal, CEO of Lytix Biopharma. "Their collective experience across scientific, clinical, and commercial areas will strengthen our capabilities to accelerate development, expand partnerships, and strengthen our position within the immuno-oncology space."

The Company would also like to extend its sincere thanks to the outgoing board members - Marie Roskrow (Chair), Jayson Rieger, and Evelina Vågesjö - for their service and valuable contributions. Their efforts have been appreciated and have helped position Lytix for the next phase of development.

Minutes of the meeting are attached hereto.

The minutes and all documents relevant for the annual general meeting are available on the Company's website: www.lytixbiopharma.com.

For more information, please contact:

Gjest Breistein, CFO

+47 952 60 512

gjest.breistein@lytixbiopharma.com

About Lytix

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.